Quantitative imaging of protein targets in the human brain with PET

PET imaging of proteins in the human brain with high affinity radiolabelled molecules has a history stretching back over 30 years. During this period the portfolio of protein targets that can be imaged has increased significantly through successes in radioligand discovery and development. This portfolio now spans six major categories of proteins; G-protein coupled receptors, membrane transporters, ligand gated ion channels, enzymes, misfolded proteins and tryptophan-rich sensory proteins. In parallel to these achievements in radiochemical sciences there have also been significant advances in the quantitative analysis and interpretation of the imaging data including the development of methods for image registration, image segmentation, tracer compartmental modeling, reference tissue kinetic analysis and partial volume correction. In this review, we analyze the activity of the field around each of the protein targets in order to give a perspective on the historical focus and the possible future trajectory of the field. The important neurobiology and pharmacology is introduced for each of the six protein classes and we present established radioligands for each that have successfully transitioned to quantitative imaging in humans. We present a standard quantitative analysis workflow for these radioligands which takes the dynamic PET data, associated blood and anatomical MRI data as the inputs to a series of image processing and bio-mathematical modeling steps before outputting the outcome measure of interest on either a regional or parametric image basis. The quantitative outcome measures are then used in a range of different imaging studies including tracer discovery and development studies, cross sectional studies, classification studies, intervention studies and longitudinal studies. Finally we consider some of the confounds, challenges and subtleties that arise in practice when trying to quantify and interpret PET neuroimaging data including motion artifacts, partial volume effects, age effects, image registration and normalization, input functions and metabolites, parametric imaging, receptor internalization and genetic factors.

[1]  E. Hansson,et al.  Astrocyte–endothelial interactions at the blood–brain barrier , 2006, Nature Reviews Neuroscience.

[2]  T. Jones,et al.  Spectral Analysis of Dynamic PET Studies , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[3]  Xiao Jin,et al.  Evaluation of Frame-Based and Event-by-Event Motion-Correction Methods for Awake Monkey Brain PET Imaging , 2014, The Journal of Nuclear Medicine.

[4]  R. Frackowiak,et al.  Monitoring by PET of macrophage accumulation in brain after ischaemic stroke , 1992, The Lancet.

[5]  M. Nedergaard,et al.  The blood–brain barrier: an overview Structure, regulation, and clinical implications , 2004, Neurobiology of Disease.

[6]  Roger N Gunn,et al.  Characterising the plasma-target occupancy relationship of the neurokinin antagonist GSK1144814 with PET , 2014, Journal of psychopharmacology.

[7]  B. Lopresti,et al.  The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: From pathology to imaging , 2006, Progress in Neurobiology.

[8]  Richard E. Carson,et al.  Comment: The EM Parametric Image Reconstruction Algorithm , 1985 .

[9]  B. Tavitian,et al.  Current paradigm of the 18-kDa translocator protein (TSPO) as a molecular target for PET imaging in neuroinflammation and neurodegenerative diseases , 2011, Insights into Imaging.

[10]  N. Volkow,et al.  Neuropharmacological actions of cigarette smoke: brain monoamine oxidase B (MAO B) inhibition. , 1998, Journal of addictive diseases.

[11]  David Goldman,et al.  Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain. , 2006, The American journal of psychiatry.

[12]  G. Ecker,et al.  Development of potential selective and reversible pyrazoline based MAO-B inhibitors as MAO-B PET tracer precursors and reference substances for the early detection of Alzheimer's disease. , 2014, Bioorganic & medicinal chemistry letters.

[13]  Ciprian Catana,et al.  MRI-Assisted PET Motion Correction for Neurologic Studies in an Integrated MR-PET Scanner , 2011, The Journal of Nuclear Medicine.

[14]  Victoria Arango,et al.  Regional Heterogeneity of 5-HT1A Receptors in Human Cerebellum as Assessed by Positron Emission Tomography , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[15]  Alan A. Wilson,et al.  Translocator Protein (18 kDa) Polymorphism (rs6971) Explains in-vivo Brain Binding Affinity of the PET Radioligand [18F]-FEPPA , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[16]  Roger N Gunn,et al.  Positron Emission Tomography Compartmental Models: A Basis Pursuit Strategy for Kinetic Modeling , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[17]  L. Marner,et al.  Age and sex effects on 5-HT4 receptors in the human brain: A [11C]SB207145 PET study , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[18]  W. Jusko,et al.  Pharmacokinetics of Capacity‐Limited Systems , 1989, Journal of clinical pharmacology.

[19]  H. N. Wagner,et al.  Multicompartmental Analysis of [11C]-Carfentanil Binding to Opiate Receptors in Humans Measured by Positron Emission Tomography , 1989, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[20]  Mark Slifstein,et al.  Measurement of the Proportion of D2 Receptors Configured in State of High Affinity for Agonists in Vivo: A Positron Emission Tomography Study Using [11C]N-Propyl-norapomorphine and [11C]Raclopride in Baboons , 2005, Journal of Pharmacology and Experimental Therapeutics.

[21]  Robert B. Innis,et al.  Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation , 2008, NeuroImage.

[22]  D L Hill,et al.  Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. , 1997, Medical physics.

[23]  R. Upadhyay Drug Delivery Systems, CNS Protection, and the Blood Brain Barrier , 2014, BioMed research international.

[24]  J C Mazziotta,et al.  Modelling approach for separating blood time-activity curves in positron emission tomographic studies. , 1991, Physics in medicine and biology.

[25]  Guy Marchal,et al.  Multimodality image registration by maximization of mutual information , 1997, IEEE Transactions on Medical Imaging.

[26]  Alan A. Wilson,et al.  Neuroinflammation in healthy aging: A PET study using a novel Translocator Protein 18kDa (TSPO) radioligand, [18F]-FEPPA , 2014, NeuroImage.

[27]  Sylvain Houle,et al.  High-Affinity States of Human Brain Dopamine D2/3 Receptors Imaged by the Agonist [11C]-(+)-PHNO , 2006, Biological Psychiatry.

[28]  Juha Koikkalainen,et al.  Fast and robust multi-atlas segmentation of brain magnetic resonance images , 2010, NeuroImage.

[29]  K. Herholz,et al.  Brain receptor imaging. , 2010, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  Kewei Chen,et al.  Image-Derived Input Function for Brain PET Studies: Many Challenges and Few Opportunities , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[31]  J. Dalley,et al.  Applications of positron emission tomography in animal models of neurological and neuropsychiatric disorders , 2012, Neuroscience & Biobehavioral Reviews.

[32]  Ming-Rong Zhang,et al.  PET applications in animal models of neurodegenerative and neuroinflammatory disorders. , 2012, Current topics in behavioral neurosciences.

[33]  M. Folstein,et al.  EFFECTS OF AGE ON DOPAMINE AND SEROTONIN RECEPTORS MEASURED BY POSITRON TOMOGRAPHY IN THE LIVING HUMAN BRAIN , 1984, Science.

[34]  W. Klunk,et al.  Impact of amyloid imaging on drug development in Alzheimer's disease. , 2007, Nuclear medicine and biology.

[35]  Jeih-San Liow,et al.  D2 dopamine receptor internalization prolongs the decrease of radioligand binding after amphetamine: A PET study in a receptor internalization-deficient mouse model , 2010, NeuroImage.

[36]  Jeih-San Liow,et al.  Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand , 2009, NeuroImage.

[37]  Lisa A. Weissfeld,et al.  Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET , 2010, NeuroImage.

[38]  Patrick Dupont,et al.  Evaluation of anatomy based reconstruction for partial volume correction in brain FDG-PET , 2004, NeuroImage.

[39]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[40]  J. Trojanowski,et al.  Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies , 2009, Nature Reviews Drug Discovery.

[41]  J. Logan Graphical analysis of PET data applied to reversible and irreversible tracers. , 1999, Nuclear medicine and biology.

[42]  Richard E Carson,et al.  Noise Reduction in the Simplified Reference Tissue Model for Neuroreceptor Functional Imaging , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[43]  D. Marquardt An Algorithm for Least-Squares Estimation of Nonlinear Parameters , 1963 .

[44]  G. Schwarz Estimating the Dimension of a Model , 1978 .

[45]  John D. Beaver,et al.  Mathematical modelling of [11C]-(+)-PHNO human competition studies , 2013, NeuroImage.

[46]  Sung-Cheng Huang,et al.  Linear regression with spatial constraint to generate parametric images of ligand-receptor dynamic PET studies with a simplified reference tissue model , 2003, NeuroImage.

[47]  Jeih-San Liow,et al.  Downregulation of Brain Phosphodiesterase Type IV Measured with 11C-(R)-Rolipram Positron Emission Tomography in Major Depressive Disorder , 2012, Biological Psychiatry.

[48]  E. Hoffman,et al.  Quantitation in Positron Emission Computed Tomography: 1. Effect of Object Size , 1979, Journal of computer assisted tomography.

[49]  J. Links,et al.  Assessment of dopamine receptor densities in the human brain with carbon‐11‐labeled N‐methylspiperone , 1984, Annals of neurology.

[50]  Stefano Zamuner,et al.  Prediction of Repeat-Dose Occupancy from Single-Dose Data: Characterisation of the Relationship between Plasma Pharmacokinetics and Brain Target Occupancy , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[51]  R. Parsey,et al.  Binding to Metabotropic Glutamate Receptor Subtype 5 , 2014 .

[52]  T Jones,et al.  In vivo disturbance of the oxidative metabolism of glucose in human cerebral gliomas , 1983, Annals of neurology.

[53]  Susan P. Hume,et al.  Quantification of PET studies with the high affinity D2/D3 receptor ligand [C-11]FLB-457: Re-evaluation of the validity of using a cerebellar reference region , 2005 .

[54]  Charles F. Reynolds,et al.  Reduced binding of [ 18 F ]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction , 1998, Brain Research.

[55]  Sébastien Ourselin,et al.  Markov random field and Gaussian mixture for segmented MRI-based partial volume correction in PET , 2012, Physics in medicine and biology.

[56]  Nathalie Ginovart,et al.  Imaging the Dopamine System with In Vivo [11C]raclopride Displacement Studies: Understanding the True Mechanism , 2005, Molecular Imaging and Biology.

[57]  Anil Kumar,et al.  Characterization of [11C]RO5013853, a novel PET tracer for the glycine transporter type 1 (GlyT1) in humans , 2013, NeuroImage.

[58]  E. M. Renkin Effects of blood flow on diffusion kinetics in isolated, perfused hindlegs of cats; a double circulation hypothesis. , 1955, The American journal of physiology.

[59]  Joanna L. Sharman,et al.  IUPHAR-DB: updated database content and new features , 2012, Nucleic Acids Res..

[60]  Claudia Kuntner,et al.  Quantitative preclinical PET imaging: opportunities and challenges , 2014, Front. Physics.

[61]  L. Rajendran,et al.  Subcellular targeting strategies for drug design and delivery , 2010, Nature Reviews Drug Discovery.

[62]  J. Hatazawa,et al.  6-[18F]Fluorodopa metabolism in patients with hemiparkinsonism studied by positron emission tomography , 1993, Journal of the Neurological Sciences.

[63]  W. Klunk,et al.  Imaging Tau Deposits In Vivo: Progress in Viewing More of The Proteopathy Picture , 2013, Neuron.

[64]  Peter C. Searson,et al.  The blood-brain barrier: an engineering perspective , 2013, Front. Neuroeng..

[65]  R. Bellman,et al.  On structural identifiability , 1970 .

[66]  Stina Syvänen,et al.  Predicting brain concentrations of drug using positron emission tomography and venous input: modeling of arterial-venous concentration differences , 2006, European Journal of Clinical Pharmacology.

[67]  R. Myers,et al.  Quantitation of Carbon‐11‐labeled raclopride in rat striatum using positron emission tomography , 1992, Synapse.

[68]  John D. Beaver,et al.  PET imaging of dopamine D3 receptors in humans with [11C]-(+)-PHNO: dissection of PHNO signal using two highly selective D3 antagonists , 2010, NeuroImage.

[69]  R P Williams,et al.  Noninvasive grading of musculoskeletal tumors using PET. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[70]  Making drug development visible--and viable. , 2014, Drug discovery today.

[71]  Paul Edison,et al.  Reference Region Automatic Extraction in Dynamic [11C]PIB , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[72]  Albert Gjedde,et al.  Subchronic Haloperidol Downregulates Dopamine Synthesis Capacity in the Brain of Schizophrenic Patients In Vivo , 2003, Neuropsychopharmacology.

[73]  C. Halldin,et al.  Test–retest reliability of [11C]AZ10419369 binding to 5-HT1B receptors in human brain , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[74]  B. Ruggeri,et al.  Animal models of human disease: challenges in enabling translation. , 2014, Biochemical pharmacology.

[75]  S. DeKosky,et al.  Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[76]  H. Watabe,et al.  Validation of noninvasive quantification of rCBF compared with dynamic/integral method by using positron emission tomography and oxygen-15 labeled water , 1995, Annals of nuclear medicine.

[77]  Andrew B. Lawson,et al.  Spatial cluster modelling , 2002 .

[78]  Patrick W. Stroman,et al.  Spatial normalization, bulk motion correction and coregistration for functional magnetic resonance imaging of the human cervical spinal cord and brainstem. , 2008, Magnetic resonance imaging.

[79]  Peter Herscovitch,et al.  Correction of Positron Emission Tomography Data for Cerebral Atrophy , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[80]  Karmen K. Yoder,et al.  ntPET: A New Application of PET Imaging for Characterizing the Kinetics of Endogenous Neurotransmitter Release , 2005 .

[81]  R. Parsey,et al.  In Vivo Ketamine-Induced Changes in [11C]ABP688 Binding to Metabotropic Glutamate Receptor Subtype 5 , 2015, Biological Psychiatry.

[82]  John Ashburner,et al.  Quantitation of [11C]diprenorphine cerebral kinetics in man acquired by PET using presaturation, pulse-chase and tracer-only protocols , 1994, Journal of Neuroscience Methods.

[83]  Christopher C Rowe,et al.  Tau imaging: early progress and future directions , 2015, The Lancet Neurology.

[84]  Bruce R. Rosen,et al.  Cortical surface-based analysis reduces bias and variance in kinetic modeling of brain PET data , 2014, NeuroImage.

[85]  Mark Slifstein,et al.  Translational characterization of [11C]GSK931145, a PET ligand for the glycine transporter type 1 , 2011, Synapse.

[86]  Arthur W. Toga,et al.  Investigation of partial volume correction methods for brain FDG PET studies , 1996 .

[87]  W C Eckelman,et al.  Quantification of Amphetamine-Induced Changes in [11C]Raclopride Binding with Continuous Infusion , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[88]  V. Ikonomidou,et al.  Translocator Protein PET Imaging for Glial Activation in Multiple Sclerosis , 2011, Journal of Neuroimmune Pharmacology.

[89]  G. Alexander,et al.  Characterization of the image-derived carotid artery input function using independent component analysis for the quantitation of [18F] fluorodeoxyglucose positron emission tomography images , 2007, Physics in medicine and biology.

[90]  Francis J McMahon,et al.  In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease. , 2013, Brain : a journal of neurology.

[91]  Marie-Claude Asselin,et al.  Quantification of PET Studies with the Very High-Affinity Dopamine D2/D3 Receptor Ligand [11C]FLB 457: Re-Evaluation of the Validity of using a Cerebellar Reference Region , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[92]  Julie C Price,et al.  Age, Sex, and Reproductive Hormone Effects on Brain Serotonin-1A and Serotonin-2A Receptor Binding in a Healthy Population , 2011, Neuropsychopharmacology.

[93]  M E Phelps,et al.  Quantitation in Positron Emission Computed Tomography: 3. Effect of Sampling , 1980, Journal of computer assisted tomography.

[94]  Mark Jenkinson,et al.  Imaging dopamine receptors in humans with [11C]-(+)-PHNO: Dissection of D3 signal and anatomy , 2011, NeuroImage.

[95]  Zsolt Szabo,et al.  Positron emission tomography imaging of serotonin transporters in the human brain using [11C](+)McN5652 , 1995, Synapse.

[96]  A Malizia,et al.  First delineation of 5-HT1A receptors in human brain with PET and [11C]WAY-100635. , 1995, European journal of pharmacology.

[97]  Min-Ying Su,et al.  Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. , 2014, Journal of Alzheimer's disease : JAD.

[98]  Sylvain Houle,et al.  Effects of aging on 5‐HT2AR binding: a HRRT PET study with and without partial volume corrections , 2011, International journal of geriatric psychiatry.

[99]  M. Laruelle,et al.  Imaging the D3 receptor in humans in vivo using [11C](+)-PHNO positron emission tomography (PET). , 2010, The international journal of neuropsychopharmacology.

[100]  Roger N Gunn,et al.  An 18-kDa Translocator Protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28 , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[101]  Elizabeth Head,et al.  Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers , 2007, Molecular Neurodegeneration.

[102]  Ronald Boellaard,et al.  Optimization of supervised cluster analysis for extracting reference tissue input curves in (R)-[11C]PK11195 brain PET studies , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[103]  S. DeKosky,et al.  Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease , 2008, Brain : a journal of neurology.

[104]  Alan A. Wilson,et al.  Quantification of Human Opiate Receptor Concentration and Affinity Using High and Low Specific Activity [11C]Diprenorphine and Positron Emission Tomography , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[105]  Olivier Salvado,et al.  MR-Less High Dimensional Spatial Normalization of 11C PiB PET Images on a Population of Elderly, Mild Cognitive Impaired and Alzheimer Disease Patients , 2008, MICCAI.

[106]  Marc Laruelle,et al.  The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development , 2002, European Neuropsychopharmacology.

[107]  D E Kuhl,et al.  Compartmental Analysis of [11C]Flumazenil Kinetics for the Estimation of Ligand Transport Rate and Receptor Distribution Using Positron Emission Tomography , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[108]  Marc Laruelle,et al.  Within-Subject Comparison of [11C]-( + )-PHNO and [11C]raclopride Sensitivity to Acute Amphetamine Challenge in Healthy Humans , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[109]  Robert B. Innis,et al.  Mixed-Affinity Binding in Humans with 18-kDa Translocator Protein Ligands , 2011, The Journal of Nuclear Medicine.

[110]  Kenneth A Krohn,et al.  Interpreting enzyme and receptor kinetics: keeping it simple, but not too simple. , 2003, Nuclear medicine and biology.

[111]  J. Melichar,et al.  Benzodiazepine dependence and its treatment with low dose flumazenil , 2014, British journal of clinical pharmacology.

[112]  N. Volkow,et al.  Imaging the norepinephrine transporter in humans with (S,S)-[11C]O-methyl reboxetine and PET: problems and progress. , 2007, Nuclear medicine and biology.

[113]  Mark Slifstein,et al.  Revisiting an Old Issue: The Discrepancy Between Tissue Ratio–Derived Binding Parameters and Kinetic Modeling–Derived Parameters After a Bolus of the Serotonin Transporter Radioligand 123I-ADAM , 2008, Journal of Nuclear Medicine.

[114]  Stephen M. Smith,et al.  Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm , 2001, IEEE Transactions on Medical Imaging.

[115]  Mark Slifstein,et al.  Impact of D2 Receptor Internalization on Binding Affinity of Neuroimaging Radiotracers , 2010, Neuropsychopharmacology.

[116]  Yuan-Hwa Chou,et al.  [(11)C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. , 2003, European journal of nuclear medicine and molecular imaging.

[117]  C. Crone,et al.  THE PERMEABILITY OF CAPILLARIES IN VARIOUS ORGANS AS DETERMINED BY USE OF THE 'INDICATOR DIFFUSION' METHOD. , 1963, Acta physiologica Scandinavica.

[118]  Kenneth Levenberg A METHOD FOR THE SOLUTION OF CERTAIN NON – LINEAR PROBLEMS IN LEAST SQUARES , 1944 .

[119]  Roger N Gunn,et al.  Quantification of the Specific Translocator Protein Signal of 18F-PBR111 in Healthy Humans: A Genetic Polymorphism Effect on In Vivo Binding , 2013, The Journal of Nuclear Medicine.

[120]  Robert B. Innis,et al.  Strategies to Improve Neuroreceptor Parameter Estimation by Linear Regression Analysis , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[121]  J. Krystal,et al.  Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. , 1998, The American journal of psychiatry.

[122]  Jennifer M. Coughlin,et al.  Regional brain distribution of translocator protein using [11C]DPA-713 PET in individuals infected with HIV , 2014, Journal of NeuroVirology.

[123]  Stephen M Smith,et al.  Fast robust automated brain extraction , 2002, Human brain mapping.

[124]  P. Cumming,et al.  PET radiopharmaceuticals for probing enzymes in the brain. , 2013, American journal of nuclear medicine and molecular imaging.

[125]  Yuan-Hwa Chou,et al.  [11C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[126]  Ralph Myers,et al.  Assessment of Spatial Normalization of PET Ligand Images Using Ligand-Specific Templates , 1999, NeuroImage.

[127]  P. Follesa,et al.  Flumazenil selectively prevents the increase in α4‐subunit gene expression and an associated change in GABAA receptor function induced by ethanol withdrawal , 2007, Journal of neurochemistry.

[128]  Guobao Wang,et al.  Direct reconstruction of dynamic PET parametric images using sparse spectral representation , 2009, 2009 IEEE International Symposium on Biomedical Imaging: From Nano to Macro.

[129]  C S Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[130]  Jeih-San Liow,et al.  Linearized Reference Tissue Parametric Imaging Methods: Application to [11C]DASB Positron Emission Tomography Studies of the Serotonin Transporter in Human Brain , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[131]  R. Narendran,et al.  Decreased Vesicular Monoamine Transporter Type 2 Availability in the Striatum Following Chronic Cocaine Self-Administration in Nonhuman Primates , 2015, Biological Psychiatry.

[132]  C Crouzel,et al.  Quantification of Benzodiazepine Receptors in Human Brain Using PET, [11C]Flumazenil, and a Single-Experiment Protocol , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[133]  R. Boellaard,et al.  Test-retest variability of quantitative [11C]PIB studies in Alzheimer’s disease , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[134]  Richard E Carson,et al.  Cerebral blood flow with [15O]water PET studies using an image-derived input function and MR-defined carotid centerlines , 2013, Physics in medicine and biology.

[135]  Lutz Tellmann,et al.  Image-derived input function obtained in a 3TMR-brainPET , 2013 .

[136]  J. Ashburner,et al.  Nonlinear spatial normalization using basis functions , 1999, Human brain mapping.

[137]  N. Volkow,et al.  Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[138]  H. Mayberg,et al.  Correction of PET Data for Partial Volume Effects in Human Cerebral Cortex by MR Imaging , 1990, Journal of computer assisted tomography.

[139]  G. Sedvall,et al.  An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET , 2004, Psychopharmacology.

[140]  Gwenn S. Smith,et al.  Analyses of [18F]altanserin bolus injection PET data. II: Consideration of radiolabeled metabolites in humans , 2001, Synapse.

[141]  C. Halldin,et al.  PET imaging of central 5-HT2A receptors with carbon-11-MDL 100,907. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[142]  C. Jack,et al.  Application of the National Institute on Aging–Alzheimer’s Association AD criteria to ADNI , 2013, Neurology.

[143]  Majaz Moonis,et al.  Amyloid Deposition Begins in the Striatum of Presenilin-1 Mutation Carriers from Two Unrelated Pedigrees , 2007, The Journal of Neuroscience.

[144]  M. Laruelle,et al.  Unexpectedly high affinity of a novel histamine H3 receptor antagonist, GSK239512, in vivo in human brain, determined using PET , 2014, British journal of pharmacology.

[145]  I. Buvat,et al.  A review of partial volume correction techniques for emission tomography and their applications in neurology, cardiology and oncology , 2012, Physics in medicine and biology.

[146]  W. Klunk,et al.  Development of positron emission tomography β-amyloid plaque imaging agents. , 2012, Seminars in nuclear medicine.

[147]  M Laruelle,et al.  Alterations of benzodiazepine receptors in type II alcoholic subjects measured with SPECT and [123I]iomazenil. , 1998, The American journal of psychiatry.

[148]  Robert B. Innis,et al.  SPECT Quantification of [123I]Iomazenil Binding to Benzodiazepine Receptors in Nonhuman Primates: II. Equilibrium Analysis of Constant Infusion Experiments and Correlation with in vitro Parameters , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[149]  A. Rehemtulla,et al.  Molecular Imaging , 2009, Methods in Molecular Biology.

[150]  Karl J. Friston,et al.  Spatial normalization of lesioned brains: Performance evaluation and impact on fMRI analyses , 2007, NeuroImage.

[151]  Michael Kassiou,et al.  The Translocator Protein , 2011, The Journal of Nuclear Medicine.

[152]  Kjell Någren,et al.  Measurement of Serotonin 5-HT1A Receptor Binding Using Positron Emission Tomography and [carbonyl-11C]WAY-100635—Considerations on the Validity of Cerebellum as a Reference Region , 2007 .

[153]  T. Jones,et al.  Parametric image reconstruction using spectral analysis of PET projection data. , 1998, Physics in medicine and biology.

[154]  R. P. Maguire,et al.  Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[155]  P. Piccini Dopamine transporter: Basic aspects and neuroimaging , 2003, Movement disorders : official journal of the Movement Disorder Society.

[156]  Kazuhiko Yanai,et al.  Tau PET Imaging in Alzheimer’s Disease , 2014, Current Neurology and Neuroscience Reports.

[157]  Patrick L. McGeer,et al.  Molecular Neurobiology of the Mammalian Brain , 1978, Springer US.

[158]  Lutz Tellmann,et al.  MR-Based PET Motion Correction Procedure for Simultaneous MR-PET Neuroimaging of Human Brain , 2012, PloS one.

[159]  B. Lopresti,et al.  Implementation and performance of an optical motion tracking system for high resolution brain PET imaging , 1998, 1998 IEEE Nuclear Science Symposium Conference Record. 1998 IEEE Nuclear Science Symposium and Medical Imaging Conference (Cat. No.98CH36255).

[160]  A. Lammertsma,et al.  Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.

[161]  Moors Pieter,et al.  Test-retest reliability. , 2014 .

[162]  Roger N. Gunn,et al.  Tracer Kinetic Modeling of the 5-HT1AReceptor Ligand [carbonyl-11C]WAY-100635 for PET , 1998, NeuroImage.

[163]  S. Kapur,et al.  Phosphodiesterase 10A PET Radioligand Development Program: From Pig to Human , 2014, The Journal of Nuclear Medicine.

[164]  M. Modat,et al.  The importance of appropriate partial volume correction for PET quantification in Alzheimer’s disease , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[165]  H R Schelbert,et al.  Blood flow and metabolism by PET. , 1994, Cardiology clinics.

[166]  D. Nutt,et al.  Imaging Endogenous Opioid Peptide Release with [11C]Carfentanil and [3H]Diprenorphine: Influence of Agonist-Induced Internalization , 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[167]  J. Mazziotta,et al.  PET imaging of neuropathology in tauopathies: progressive supranuclear palsy. , 2013, Journal of Alzheimer's disease : JAD.

[168]  D. Nutt,et al.  Influence of agonist induced internalization on [3H]Ro15‐4513 binding—an application to imaging fluctuations in endogenous GABA with positron emission tomography , 2015, Synapse.

[169]  Roger N. Gunn,et al.  Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals , 1998, European Journal of Nuclear Medicine.

[170]  P. Grasby,et al.  Characterisation of the appearance of radioactive metabolites in monkey and human plasma from the 5-HT1A receptor radioligand, [carbonyl-11C]WAY-100635--explanation of high signal contrast in PET and an aid to biomathematical modelling. , 1998, Nuclear medicine and biology.

[171]  W. Birkfellner,et al.  Application of image-derived and venous input functions in major depression using [carbonyl-(11)C]WAY-100635. , 2013, Nuclear medicine and biology.

[172]  Peter Herscovitch,et al.  Comparison of Bolus and Infusion Methods for Receptor Quantitation: Application to [18F]Cyclofoxy and Positron Emission Tomography , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[173]  F Fazio,et al.  Importance of partial-volume correction in brain PET studies. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[174]  M. Mintun,et al.  A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.

[175]  Nick C Fox,et al.  11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study , 2010, The Lancet Neurology.

[176]  Elliot A Stein,et al.  Greater Nicotinic Acetylcholine Receptor Density in Smokers Than in Nonsmokers: A PET Study with 2-18F-FA-85380 , 2008, Journal of Nuclear Medicine.

[177]  Mark Slifstein,et al.  Monoamine Transporter Occupancy of a Novel Triple Reuptake Inhibitor in Baboons and Humans Using Positron Emission Tomography Clinical Imaging , 2022 .

[178]  Paolo Zanotti-Fregonara,et al.  Kinetic analysis of [11C]befloxatone in the human brain, a selective radioligand to image monoamine oxidase A , 2013, EJNMMI Research.

[179]  W. Klunk,et al.  Positron emission tomography radioligands for in vivo imaging of Aβ plaques. , 2013, Journal of labelled compounds & radiopharmaceuticals.

[180]  C. Masters,et al.  The challenges of tau imaging , 2012 .

[181]  J. Hirvonen,et al.  Increased In Vivo Expression of an Inflammatory Marker in Temporal Lobe Epilepsy , 2012, The Journal of Nuclear Medicine.

[182]  M. Laruelle,et al.  Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies , 1999, Journal of psychopharmacology.

[183]  Yu-Shin Ding,et al.  PET imaging of norepinephrine transporters. , 2006, Current pharmaceutical design.

[184]  E. W. EMERY,et al.  Compartmental Analysis , 1970, Nature.

[185]  Rainer E. Martin,et al.  G protein-coupled receptor transmembrane binding pockets and their applications in GPCR research and drug discovery: a survey. , 2011, Current topics in medicinal chemistry.

[186]  Vincent Doré,et al.  In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[187]  R. Millar,et al.  The year in G protein-coupled receptor research. , 2010, Molecular endocrinology.

[188]  C. Halldin,et al.  Quantitative analyses of carbonyl-carbon-11-WAY-100635 binding to central 5-hydroxytryptamine-1A receptors in man. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[189]  Agneta Nordberg,et al.  Nicotinic receptor abnormalities of Alzheimer’s disease: therapeutic implications , 2001, Biological Psychiatry.

[190]  E. Hoffman,et al.  Quantitation in positron emission computed tomography: 2. Effects of inaccurate attenuation correction. , 1979, Journal of computer assisted tomography.

[191]  Michael Brady,et al.  A Biomathematical Modeling Approach to Central Nervous System Radioligand Discovery and Development , 2009, Journal of Nuclear Medicine.

[192]  D. Feng,et al.  Noninvasive Quantification of the Cerebral Metabolic Rate for Glucose Using Positron Emission Tomography, 18F-Fluoro-2-Deoxyglucose, the Patlak Method, and an Image-Derived Input Function , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[193]  Jerry L Prince,et al.  Measurement of Radiotracer Concentration in Brain Gray Matter Using Positron Emission Tomography: MRI-Based Correction for Partial Volume Effects , 1992, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[194]  S. Kety The theory and applications of the exchange of inert gas at the lungs and tissues. , 1951, Pharmacological reviews.

[195]  Philip J. Noonan,et al.  The design and initial calibration of an optical tracking system using the Microsoft Kinect , 2011, 2011 IEEE Nuclear Science Symposium Conference Record.

[196]  Lisa A. Weissfeld,et al.  Assessment of parameter settings for SPM5 spatial normalization of structural MRI data: Application to type 2 diabetes , 2008, NeuroImage.

[197]  Alessandro Sardini,et al.  Agonist‐dependent internalization of D2 receptors: Imaging quantification by confocal microscopy , 2007, Synapse.

[198]  H. Akaike A new look at the statistical model identification , 1974 .

[199]  R B Banati,et al.  In vivo visualization of activated glia by [11C] (R)-PK11195-PET following herpes encephalitis reveals projected neuronal damage beyond the primary focal lesion. , 2001, Brain : a journal of neurology.

[200]  Claus Svarer,et al.  Cerebral serotonin transporter binding is inversely related to body mass index , 2010, NeuroImage.

[201]  Rajendra D. Badgaiyan,et al.  A novel method for noninvasive detection of neuromodulatory changes in specific neurotransmitter systems , 2003, NeuroImage.

[202]  S. Stone-Elander,et al.  Stereoselective binding of 11C-raclopride in living human brain — a search for extrastriatal central D2-dopamine receptors by PET , 2004, Psychopharmacology.

[203]  M. Laruelle Imaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[204]  Arthur Christopoulos,et al.  Emerging paradigms in GPCR allostery: implications for drug discovery , 2013, Nature Reviews Drug Discovery.

[205]  Z. Bhagwagar,et al.  Age Effects on Serotonin Receptor 1B as Assessed by PET , 2012, The Journal of Nuclear Medicine.

[206]  J. Trojanowski,et al.  Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls , 2013, Neuron.

[207]  R. Zipursky,et al.  PET and SPECT Imaging in Psychiatric Disorders , 2007, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[208]  D E Kuhl,et al.  Dual-[11C]Tracer Single-Acquisition Positron Emission Tomography Studies , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[209]  Wufan Chen,et al.  3.5D dynamic PET image reconstruction incorporating kinetics-based clusters , 2012, Physics in medicine and biology.

[210]  André Luxen,et al.  PET radiotracers for molecular imaging in the brain: Past, present and future , 2012, NeuroImage.

[211]  Mark Slifstein,et al.  Estimation of serotonin transporter parameters with 11C-DASB in healthy humans: reproducibility and comparison of methods. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[212]  François Mauguière,et al.  Seizure-related short-term plasticity of benzodiazepine receptors in partial epilepsy: a [11C]flumazenil-PET study. , 2005, Brain : a journal of neurology.

[213]  J. Levin Emission Tomographic Studies in Substance Abuse , 2001 .

[214]  El Mostafa Fadaili,et al.  Comparison of Eight Methods for the Estimation of the Image-Derived Input Function in Dynamic [18F]-FDG PET Human Brain Studies , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[215]  Kjell Någren,et al.  Measurement of central µ-opioid receptor binding in vivo with PET and [11C]carfentanil: a test–retest study in healthy subjects , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[216]  Masahiro Fujita,et al.  Comparison of [11C]-(R)-PK 11195 and [11C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: Implications for positron emission tomographic imaging of this inflammation biomarker , 2010, NeuroImage.

[217]  G. Alexander,et al.  Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.

[218]  Alan A. Wilson,et al.  Evaluation of 11C-GSK189254 as a Novel Radioligand for the H3 Receptor in Humans Using PET , 2010, Journal of Nuclear Medicine.

[219]  Patrick Dupont,et al.  [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor , 2007, Proceedings of the National Academy of Sciences.

[220]  N. Volkow,et al.  BMI Modulates Calorie-Dependent Dopamine Changes in Accumbens from Glucose Intake , 2014, PloS one.

[221]  J J DiStefano,et al.  Multiexponential, multicompartmental, and noncompartmental modeling. II. Data analysis and statistical considerations. , 1984, The American journal of physiology.

[222]  Mark Slifstein,et al.  Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. , 2003, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[223]  Alan A. Wilson,et al.  Imaging Dopamine D3 Receptors in the Human Brain with Positron Emission Tomography, [11C]PHNO, and a Selective D3 Receptor Antagonist , 2010, Biological Psychiatry.

[224]  C Crouzel,et al.  PET study of carbon-11-PK 11195 binding to peripheral type benzodiazepine sites in glioblastoma: a case report. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[225]  Vladimir Kepe,et al.  PET scanning of brain tau in retired national football league players: preliminary findings. , 2013, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[226]  A. Evans,et al.  Correction for partial volume effects in PET: principle and validation. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[227]  Mark Slifstein,et al.  Measuring Drug Occupancy in the Absence of a Reference Region: The Lassen Plot Re-Visited , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[228]  P. Morgan,et al.  The Cubic Ternary Complex ReceptorOccupancy Model I. Model Description , 1996 .

[229]  Jinsong Ouyang,et al.  MR-based motion correction for PET imaging using wired active MR microcoils in simultaneous PET-MR: phantom study. , 2014, Medical physics.

[230]  Ronald J. Jaszczak,et al.  Bayesian reconstruction and use of anatomical a priori information for emission tomography , 1996, IEEE Trans. Medical Imaging.

[231]  P. Grasby,et al.  Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11]WAY-100635 and [11C]raclopride , 2002, Journal of psychopharmacology.

[232]  M N Cantwell,et al.  Does cerebral blood flow decline in healthy aging? A PET study with partial-volume correction. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[233]  J. Kehler,et al.  PDE10A inhibitors: novel therapeutic drugs for schizophrenia. , 2011, Current pharmaceutical design.

[234]  William J. Jagust,et al.  Automated template-based PET region of interest analyses in the aging brain , 2007, NeuroImage.

[235]  W. L. Chiou,et al.  The Phenomenon and Rationale of Marked Dependence of Drug Concentration on Blood Sampling Site , 1989, Clinical pharmacokinetics.

[236]  Jeih-San Liow,et al.  Design of a motion-compensation OSEM list-mode algorithm for resolution-recovery reconstruction for the HRRT , 2003, 2003 IEEE Nuclear Science Symposium. Conference Record (IEEE Cat. No.03CH37515).

[237]  A. Rahmim,et al.  Direct 4D reconstruction of parametric images incorporating anato-functional joint entropy , 2010, 2008 IEEE Nuclear Science Symposium Conference Record.

[238]  Alan A. Wilson,et al.  Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C]DAPP and [11C]DASB , 2000, European Journal of Nuclear Medicine.

[239]  R. Lefkowitz,et al.  A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. , 1980, The Journal of biological chemistry.

[240]  L. Iversen,et al.  Neurotransmitter transporters and their impact on the development of psychopharmacology , 2006, British journal of pharmacology.

[241]  Arthur Christopoulos,et al.  Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders , 2009, Nature Reviews Drug Discovery.

[242]  W. Gordon Frankle,et al.  [11C]flumazenil Binding Is Increased in a Dose-Dependent Manner with Tiagabine-Induced Elevations in GABA Levels , 2012, PloS one.

[243]  Andrew S. Felts,et al.  Relationship between In Vivo Receptor Occupancy and Efficacy of Metabotropic Glutamate Receptor Subtype 5 Allosteric Modulators with Different In Vitro Binding Profiles , 2015, Neuropsychopharmacology.

[244]  Christer Halldin,et al.  Positron emission tomography imaging of 5-hydroxytryptamine1B receptors in Parkinson's disease , 2014, Neurobiology of Aging.